Kini o ṣẹlẹ
Biolevate, a Paris-based developer of AI-powered automation software, has raised a €30 million Series A co-led by RAISE France and Orange Ventures. The financing will support Biolevate’s international expansion, accelerate development of its enterprise AI platform, and expand deployments among pharmaceutical and other life sciences organizations.
Biolevate has raised a €30 million Series A co-led by RAISE France and Orange Ventures.
The financing will support Biolevate’s international expansion, accelerate development of its enterprise AI platform, and expand deployments among pharmaceutical and other life sciences organizations.
Biolevate’s platform combines artificial intelligence with scientific evidence, regulatory knowledge, organizational information, and governed workflows to help pharmaceutical and biotechnology companies automate research and administrative activities.
The company’s technology addresses a challenge facing the life sciences industry as organizations seek to accelerate drug discovery, clinical development, and commercialization.
Biolevate aims to reduce the administrative burden on life sciences organizations by automating complex scientific and regulatory processes.
Awọn alaye orisun: pulse2.com ↗
Kini idi ti o ṣe pataki
Biolevate’s AI-powered automation software aims to reduce the administrative burden on life sciences organizations by automating complex scientific and regulatory processes. The company’s platform combines artificial intelligence with scientific evidence, regulatory knowledge, organizational information, and governed workflows to help pharmaceutical and biotechnology companies automate research and administrative activities.
Biolevate’s AI-powered automation software has the potential to improve scientific research and identify new therapeutic candidates.
The company’s platform can accelerate systematic literature reviews and research synthesis by a factor of 16.
Biolevate’s technology can deliver an 80% efficiency improvement in regulatory intelligence and compliance activities.
The company has established partnerships across the pharmaceutical and technology industries, including relationships with Sanofi, NVIDIA, Microsoft, and regulatory organizations.
Biolevate’s new Boston office will support expansion into the U.S. pharmaceutical market.
Ibaraẹnisọrọ Mechanism: Bii O Ṣe Nṣiṣẹ Lootọ
Ṣawari imọ-ẹrọ abẹlẹ lẹhin idagbasoke yii ni ibaraenisọrọ.
Which description best fits "narrow AI", the kind of AI in use today?
Kini lati wo tókàn
Biolevate’s international expansion, development of its enterprise AI platform, and deployments among pharmaceutical and other life sciences organizations.
Biolevate’s international expansion and development of its enterprise AI platform.
The company’s deployments among pharmaceutical and other life sciences organizations.
Biolevate’s partnerships across the pharmaceutical and technology industries.
The company’s new Boston office and expansion into the U.S. pharmaceutical market.
Biolevate’s plans to double its workforce again over the next 12 months.